Versione Pdf - FeDerSerd

6
informa
of the Evidence. Journal of Addictiive Diseases. 14 (3), 1995.
• Cowan A., Lewis J. W., Buprenorphine: combatting drug abuse
with a unique opioid. Wileii-Liss, New York, NY, 1995.
• riminal Justice Institute, The Corrections Yearbook: Instant
Answers to Key Questions in Corrections (New York: Criminal
Justice Institute, 1995).
• Dole, V.P. Implications of methadone maintenance for theories
of narcotic addiction. Journal of the American Medical
Association 260(20): 3025-3029. 1988.
• Dole, V.P. and Joseph, H. Long term outcome of patients treated
with methadone maintenance. Annals of the New York
Academy of Science 311: 181-189. 1978.
• Dole, V.P. and Nyswander, M.E. A medical treatment for diacetyl
morphine (heroin) addiction: A clinical trial with methadone
hydrochloride. Journal of the American Medical Association
193: 646650. 1965.
• Doran C. M., Shanahan M., Mattick R.P., Ali R., White J., Bell J.:
Buprenorphine versus methadone maintenance: a cost- effectiveness
analysis. Drug and Alcohol Dependence 71: 295302. 2003.
• Drougalis J.L.R., Bootman J. L., Larson L.N., Mc Ghan W.F.
“Farmacoeconomia: lo stato dell’arte”. Edizione italiana a cura di
Lucioni C., Centro Informazione Sanitaria (CIS), Milano, 1991.
• Hartog J.and Tusen D.J. Valium use and abuse by metadone
maintenance clients. International Journal of Addictions 22, 1987.
• Harwood HJ, Hubbard RL, Collins JJ, Rachal JV: The cost of
crime and the benefits of drug abuse treatment: a cost-benefit
analysis using TOPS data. NIDA Res. Monogr. 86: 209-235, 1988.
Institute of Medicine. Federal Regulation of Methadone
Treatment, op. cit., 22.
• Johnson R.E., Pharm D., Chutuape M.A., Ph.D., Strain E.C., Walsh
S.L., Stitzer M.L., and Bigelow G.E.,”A comparison of levomethadyl
SPECIALE 1° PREMIO MOLTENI PER LA TOSSICODIPENDENZA
acetate, buprenorphine, and methadone for opioid dependence”.
The New England Journal of Medicine. 18, 343. 2000.
• Lowinson J.H., Marion I.J., Joseph H., Dole V.P. Methadone maintenance.
In substance abuse: a comprehensive textbook. 1992.
• Magura S., Siddiqi Q., Freeman R.C., and Lipton D.S., “Changes
in Cocaine Use After Entry to Methadone Treatment,” in
Cocaine, AIDS, and Intravenous Drug Use (New York: Haworth
Press, 1991).
• Mattick R.P., Breen C., Kimber J., Davoli M. “ Terapia con metadone
a mantenimento paragonata con terapie che non utilizzano
gli oppiacei o con terapie sostitutive per la dipendenza da
oppiacei. Cochrane Drugs and Alcohol Group. 2002.
• Mattick R.P., Kimber J., Breen C., Davoli M. “Buprenorfina a
mantenimento paragonata con il placebo o con il metadone a
mantenimento per la dipendenza da oppiacei”. Cochrane Drugs
and Alcohol Group. 2002.
• Mello N.K.,, Mendelson M.P., Bree M.P., Lukas S.E.
Buprenorphine suppresses cocaine selfadministration by rhesus
monkeys. Science 245: 859-862, 1989.
Nutt DJ. Receptor pharmacology of buprenorphine. Res. Clin.
Forums 19 (2): 9-15, 1997.
• Payte J.T., Khuri E.T. Principles of Methadone dose determination.
In State Methadone Treatment Guidelines. (Rockville, M.D.,
U.S. Department of Health Human Services), 1993.
• Villiger JW. Binding of buprenorphine to opiate receptors.
Neuropharmacol. 23 (3): 373-375, 1994.
• Ward J., Mattick R.P., Hall W. Key issues in methadone maintenance
treatment (Sydney, New South Wales University Press) 1992.
• Weddington WW, Barry S.B. Changes in mood, craving, and
sleep during short-term abstinence reported by male cocaina
addicts. Arch. Gentile Psychiatry, 47: 861-868. 1990.
Tab. 1 – Parametri ematologici dei pazienti trattati con metadone (0 = inizio follow-up, dopo 120 giorni e dopo
240 giorni); *P < 0,05